Fulvestrant: A new agent in endocrine treatment for breast cancer;Fulvestrant: Novi lijek u hormonskoj terapiji raka dojke

Lijecnicki Vjesnik

Volumn 128, Issue 1-2, 2006, Pages 31-36

  Juretić, Antonio ^a   Šarić, Nera ^a   Bišof, Vesna ^a   Bašić Koretić, Martina ^a  

^a Klinika za Onkologiju   (Croatia)

Author keywords

Antineoplastic agents, hormonal therapeutic use; Breast neoplasms drug therapy; Estradiol Analogs and derivatives, therapeutic use; Selective estrogen receptor modulators therapeutic use

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN;

EID: 33644824568     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
2. Thurlimann B, Muller A, Senn HJ. Management of primary breast cancer: an update. Onkologie 2004;27:175-9.
3. National Cancer Institute. Breast Cancer (PDQ®): Treatment. http:// www.nci.nih.gov/cancertopics/pdq/treatment/breast/health-professional. Datum pristupa 6. travnja 2005.
4. Paik S, Shak S, Tang G i sur. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004; 351:2817-26.
5. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005;23:1631-5.
6. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
7. Leake R. 100 years of the endocrine battle against breast cancer. Lancet 1996;347:1780-1.
8. Cole MP, Jones CTA, Todd IDH. A new antiestrogenic agents for breast cancer. An early appraisal of ICI 46,474. Br J Cancer 1971;25:270-5.
9. Early Breast Cancer Trialist Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
10. Fisher B, Costantino JP, Wickerham DL i sur. Tamoxifen for the prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J Natl Cancer Inst 1998;90:1371-88.
11. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
12. Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:1-32.
13. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22.
14. Rutqvist LE. Adjuvant endocrine therapy. Best Pract Res Clin Endocrinol Metab 2004;18:81-95.
15. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 2004;11:391-406.
16. Winer EP, Hudis C, Burstein HJ i sur. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23: 619-29.
17. Winer EP. Optimizing endocrine therapy for breast cancer. J Clin Oncol 2005;23:1609-10.
18. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23:1736-50.
19. Strasser-Weippl K, Goss PE. Advances in Adjuvant Hormonal Therapy for postmenopausal women. J Clin Oncol 2005;23:1751-9.
20. Tobias JS. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women. Int J Biochem Cell Biol 2004;36:2112-9.
21. Howell A, Cuzick J, Baum M i sur. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
22. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004;51:55-67.
23. Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:47-66.
24. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994;32:49-55.
25. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58.
26. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project b-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
27. Osborne CK, Bardou V, Hopp TA i sur. Role of the estrogen receptor coactivator A/B1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
28. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JMW. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer 2004;11:623-41.
29. Gradishar WJ. Tamoxifen - what next? Oncologist 2004;9:378-84.
30. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30.
31. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004;90(Suppl 1):S2-S6.
32. Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 2004;30:695-706.
33. Robertson JF, Come SE, Jones SE i sur. Endocrine treatment options for advanced breast cancer - the role of fulvestrant. Eur J Cancer 2005; 41:346-56.
34. Robertson JF, Nicholson RI, Bundred NJ i sur. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46.
35. Possinger K. Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother 2004;5:2549-58.
36. Robertson JF, Erikstein B, Osborne KC i sur. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004;43:529-38.
37. Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004;90 Suppl 1:S7-10.
38. Osborne CK, Pippen J, Jones SE i sur. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American Trial. J Clin Oncol 2002;20:3386-95.
39. Howell A, Robertson JF, Quaresma Albano J i sur. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
40. Robertson JF, Osborne CK, Howell A i sur. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38.
41. Howell A, Robertson JF, Abram P i sur. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22: 1605-13.
42. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L. Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant (žFaslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207-11.
43. Howell A. Postmenopausal women with advanced breast cancer who progress on Fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 2002;76(Suppl 1):S72.
44. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):S15-8.
45. Vergote I, Robertson JFR. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 2004;90(Suppl 1): S11-4.